Recent innovations across the multiple ADC components, such as enhanced antibody-targeting to the tumors, better linker ...

Global Antibody Drug Conjugate Market is valued at approximately USD 5.60 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 16.12% over the forecast period 2024-2030.

Roche and Genentech have announced outcomes from the randomised, multi-centre, international Phase III SUNMO trial for those ...

NextCure has ramped up its antibody-drug conjugate (ADC) pivot, penning a $745 million deal for the ex-China rights to ...

A Roots Analysis study showed the market for ADC manufacturing is $1.79 billion today, but is expected to grow to $7 billion ...

In a prostate cancer mouse model (22Rv1 xenografts), the combination of 225 Ac-YS5 (0.12 µCi) + YS5-MMAE (1.8 mg/kg) was associated with the most significant reduction in tumor volume (green curves in ...

Companies like AstraZeneca, Daiichi Sankyo, Pfizer and Merck are learning from previous setbacks in the ADC space to improve ...

As the leading cause of cancer-related death, lung cancer remains a noteworthy hazard to human health. NSCLC is the most prevalent subtype, accounting ...

In this video, Sonali M. Smith, MD, discusses several notable studies on new treatment combinations and other options for ...

The companies aim to generate preclinical proof-of-concept data on SRB123 and quickly take it into clinical trials.

The agency cleared CSL’s hereditary angioedema drug days after “resource constraints” delayed a rival medicine. Elsewhere, ...